Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768508 | 1.00 | MEN1 (0.76) | MEN1KMT2AMAPTRAB9AKDM4E | |
| SCHEMBL19504615 | 0.98 | MEN1 (0.72) | MEN1KMT2AMAPTRAB9AKDM4E | |
| SCHEMBL7335775 | 0.97 | MEN1 (0.71) | MEN1KMT2AMAPTRAB9AKDM4E | |
| SCHEMBL2980200 | 0.94 | KMT2A (0.67) | MEN1KMT2AMAPTRAB9AKDM4E | |
| SCHEMBL12768363 | 0.89 | KMT2A (0.78) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1531938 | 0.89 | KMT2A (0.78) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1531929 | 0.86 | MEN1 (1.00) | MEN1KMT2AALDH1A1HTTTDP1 | |
| SCHEMBL224471 | 0.86 | MEN1 (1.00) | MEN1KMT2AALDH1A1HTTTDP1 | |
| SCHEMBL224651 | 0.86 | MEN1 (1.00) | MEN1KMT2AALDH1A1HTTTDP1 | |
| SCHEMBL13572552 | 0.86 | KMT2A (0.70) | MEN1KMT2AMAPTRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698411-B9 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2698411-B9 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2698411-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2698411-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2698412-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2698412-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2698412-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698412-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698411-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698411-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323012-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPITCAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323012-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPITCAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158483-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158488-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | MYOC, RARG, MTX2 | MEN1 84/4885KMT2A 4121/4885MAPT 1861/4885 |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | MEN1 117/4885KMT2A 3837/4885MAPT 2243/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | MEN1 117/4885KMT2A 3837/4885MAPT 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.